From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
I recommend close monitoring of these electrolyte abnormalities with repeat labs within 1-2 weeks, as the patient's sodium level is actually lower than normal (hyponatremia), not higher, at 124 mEq/L, and the glucose level is slightly elevated at 135 mg/dL, while the chloride level is slightly low at 90 mEq/L. The patient has hyponatremia, hyperglycemia, and hypochloremia. In the meantime, the patient should increase fluid intake, particularly water, to help normalize sodium levels. The hyponatremia could be contributing to the elevated glucose, as dehydration can worsen glucose control. For the follow-up labs, I recommend a comprehensive metabolic panel (CMP) that includes sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, and calcium, as suggested by the principles outlined in 1. This will provide a more complete picture of electrolyte status and kidney function. If the patient is taking any diuretics, these may need to be temporarily adjusted. The underlying cause of these electrolyte abnormalities needs to be identified, as they could indicate kidney dysfunction, endocrine disorders, or medication effects, and a thorough evaluation should be guided by the principles of interpreting laboratory tests in the context of the patient's clinical presentation, as discussed in 2 and 3. If symptoms like confusion, weakness, or increased thirst are present, the patient should seek immediate medical attention rather than waiting for the scheduled follow-up. Key aspects to consider in the management of this patient include:
- Monitoring for signs of dehydration or electrolyte imbalance
- Adjusting medications that may be contributing to the electrolyte abnormalities
- Evaluating for underlying kidney or endocrine disorders
- Providing patient education on the importance of adequate fluid intake and the potential consequences of untreated electrolyte imbalances, as emphasized in 4.